BIO Protocol

BIO Protocol is a multi-chain financial infrastructure layer for decentralized science (DeSci), enabling researchers to tokenize scientific IP and communities to fund, govern, and earn from early-stage biotech through a network of specialized decentralized autonomous organizations called BioDAOs.

What Problem It Solves

Traditional scientific funding depends on government grants and pharmaceutical company priorities. Both mechanisms select heavily for diseases with large patient populations, leaving rare conditions and early-stage research chronically underfunded. BIO Protocol reframes the funding question: small patient communities that lack market power can still constitute a community fund. By pooling capital onchain and attaching governance rights to that capital, the protocol lets globally distributed contributors direct resources toward research that would otherwise wait decades or never launch.

The protocol's own framing calls this category "Science Finance" or SciFi — a deliberate fusion of DeFi liquidity mechanics with DeSci research coordination.

Core Mechanism

The protocol operates through five interlocking functions:

Curation. BIO token holders vote on which research teams and BioDAOs are admitted to the network. This acts as a quality filter before capital is deployed.

Funding. Admitted projects can run token sales representing their research IP's future value. Researchers receive capital in weeks rather than the years a traditional grant cycle requires. As of mid-2025, the network had facilitated $50M+ across more than 200 completed deals, with IP tokens held across 60,000+ wallets.

Liquidity. BIO tokens pair with individual BioDAO tokens in liquidity pools, generating trading fees and deepening markets for research IP. Deeper liquidity makes it easier for researchers to raise and for contributors to exit.

Bio/acc Rewards. The protocol uses BIO token emissions to incentivize BioDAOs as they hit research milestones, aligning token rewards with scientific progress rather than speculation alone.

Meta-Governance. Because the BIO treasury accumulates token allocations from each BioDAO that joins, BIO holders gain voting rights across the entire portfolio — effectively a governance index over the DeSci ecosystem.

Key Products

Intellectual Property Tokens (IPTs) are the fundraising primitive. Researchers publish a description of their project, run a token sale, and receive funding from anyone globally. IPT holders participate in the community and governance of that research project; they do not automatically receive profit distributions, though licensing revenue distribution can be structured into DAO governance.

Ignition Sales are the protocol's structured fundraising mechanism — low-cap, community-curated rounds for early-stage research projects. Access is prioritized for BIO stakers and BioXP participants, creating a flywheel where long-term stakers gain privileged access to new rounds.

BioXP is a loyalty and rewards layer. Users earn BioXP points by staking BIO tokens and participating in the ecosystem. Points translate into whitelist access and discounts on BioDAO services.

BioAgents are AI agents built on top of research knowledge graphs. A BioAgent ingests a body of research papers, constructs an organized knowledge graph, and makes that knowledge queryable — functioning as a specialized research assistant for a particular scientific domain. The first public BioAgent launched in partnership with VitaDAO and longevity researcher Dr. Aubrey de Grey; its $AUBRAI token rose roughly 150x from pre-sale valuation in its first weeks while generating over 1,000 scientific hypotheses minted onchain.

OpenLabs is a newer platform where researchers and AI agents can collaboratively turn scientific hypotheses into funded research projects, extending the protocol's infrastructure into the pre-publication research phase.

BioDAO Ecosystem

BioDAOs are the research entities that receive funding and governance through the protocol. Each focuses on a specific scientific domain and operates its own treasury and governance token. The network includes more than ten active BioDAOs:

• VitaDAO (longevity research, VITA token)
• PsyDAO (psychedelic science and mental health)
• ValleyDAO (synthetic biology and environmental biotech, GROW token)
• CryoDAO (cryopreservation, CRYO token)
• AthenaDAO (women's health research)
• CerebrumDAO (neuroscience)
• HairDAO (hair loss research)
• Curetopia (rare disease research — the first Solana-native BioDAO)
• Nootropics DAO (cognitive enhancement)
• SpineDAO (spinal health)

Each BioDAO allocates a portion of its token supply to the BIO Protocol treasury on joining, which is how the BIO token accumulates meta-governance rights across the portfolio.

The BIO Token

BIO is the native governance and utility token of the protocol. It launched on Ethereum mainnet on January 3, 2025, then deployed on Solana via the Wormhole cross-chain bridge shortly after. The token is tradeable on Binance (listed as the exchange's 63rd Launchpool project), Uniswap on Ethereum, and Jupiter on Solana.

BIO token utility includes: voting on which BioDAOs join the network, signaling support for specific research projects, gaining whitelist priority for BioDAO funding rounds, influencing protocol emission schedules, and holding meta-governance rights across BioDAO portfolios. The public Binance Launchpool listing reportedly returned up to 58x for early participants, and ecosystem market cap reached $300M+ with $65M+ held in BioDAO treasuries as of the token launch period.

Solana Presence

BIO Protocol's Solana integration goes beyond a token bridge. The protocol launched the V1 launchpad on Solana in February 2025, making BioDAO token sales accessible to Solana users natively. Curetopia, focused on rare disease research, became the first Solana-native BioDAO — running its initial auction on Solana and primarily operating on that chain. The BIO token is tradeable on Jupiter. The protocol uses Wormhole for cross-chain token movement between Ethereum, Solana, and Base.

Funding and Backers

The protocol raised $6.9M (disclosed in 2025) in a round anchored by Maelstrom Fund to launch Bio V2. Earlier backers include Binance Labs (the exchange's first DeSci investment), Pfizer Ventures, Zee Prime Capital, Boost VC, and Northpond Ventures. The Binance Labs investment was specifically directed toward expanding the BioDAO ecosystem and seeding new research organizations.

Stage and Traction

Bio V2 features — Ignition Sales, BioXP staking, and BioAgents — launched in 2025. By mid-2026, the blog reported White House-level institutional interest in open science, and projects like PeptAI (a peptide drug discovery BioDAO) had moved from onchain funding to active wet-lab experimentation. The community comprises 90,000+ members across its DAOs. The protocol positions itself as an alternative to traditional scientific grant systems at a time when public research funding in the United States and elsewhere has faced significant cuts.